- Jul 7, 2020
- 403
- Tinnitus Since
- 05/2020
- Cause of Tinnitus
- Unknown/Stress
I'll just leave it at this quote and relate it to funding.And fortunately, management & all the co-founders of the company flat out disagree with you. They say FX-322 is a very promising clinical candidate and I will take their opinion over yours. An article just came out of MIT this morning and here are a few great quotes from it:
"Some of these people [in the trials] couldn't hear for 30 years, and for the first time they said they could go into a crowded restaurant and hear what their children were saying," Langer says. "It's so meaningful to them. Obviously more needs to be done, but just the fact that you can help a small group of people is really impressive to me."
For now, Karp is already thrilled with Frequency's progress, which hit home the last time he was in Frequency's office and met a speaker who shared her experience with hearing loss.
"You always hope your work will have an impact, but it can take a long time for that to happen," Karp says. "It's been an incredible experience working with the team to bring this forward. There are already people in the trials whose hearing has been dramatically improved and their lives have been changed. That impacts interactions with family and friends. It's wonderful to be a part of."
But I know they don't mention audiograms so most everyone on Tinnitus Talk will consider it "trash results".
As for cash, you do realize that the stock price is not locked in at $2 a share for the rest of time? They have enough cash on hand to get them through to new Phase 2b results and FX-345 Phase 1 results. Management has repeatedly said that the failed trial was not due to the drug and it was due to trial design. The trial would have passed with flying colors if they didn't have the unprecedented placebo response. Once the new Phase 2b data drops for FX-322, I expect the stock price to recover some and then they will be able to issue more shares to raise capital with much less dilution but you don't seem to believe there is any possibility of that ever happening so I don't know what more to tell you.
The company hasn't been over enthusiastic about their PR, they've been quite open to the world about how they are conducting their science; much more so than most other biotechs. It's just that the desperate people who want solutions will be disappointed with anything that doesn't restore them back to perfect hearing.
So, if FX-322 gets FDA approval, can I assume you won't be taking it then?
"I wouldn't be surprised if in 10 or 15 years, because of the resources being put into this space and the incredible science being done, we can get to the point where [reversing hearing loss] would be similar to Lasik surgery, where you're in and out in an hour or two and you can completely restore your vision," Karp says. "I think we'll see the same thing for hearing loss."
You are misunderstanding my point of view. I want this company to succeed, but FX-322 is a bomb until proven otherwise. It really is. Stock price down 90% shows that in hard evidence no matter what the company says. The market does not see it as a sure thing from a commercial perspective. Quite the contrary.
This is going to take time and lots of money. Frequency Therapeutics is capitalised until end of 2023. Funding is a legitimate concern and if you can't see that then you need LASIK too.
Sorry guys, but there is a long way to go in this story. Efficacy and funding are not certain. That is beyond question and I can't continue to point the blatantly bloody obvious out repeatedly.
To answer your question regarding having a dose of FX-322, I am in no position based on the existing facts to make a decision on that, but based on Phase 2 results I would 100% not pay big money for a shot... I need to see a lot more regarding efficacy.
BUT:
FX-345, which if it does regenerate deep into the cochlea below 4,000 Hz, I would take the shot in a heartbeat and pay big money for it too.
Only time and clinical trial success will tell.